[go: up one dir, main page]

BR0008254A - Combinações para o tratamento de doenças que envolvam angiogênese - Google Patents

Combinações para o tratamento de doenças que envolvam angiogênese

Info

Publication number
BR0008254A
BR0008254A BR0008254-6A BR0008254A BR0008254A BR 0008254 A BR0008254 A BR 0008254A BR 0008254 A BR0008254 A BR 0008254A BR 0008254 A BR0008254 A BR 0008254A
Authority
BR
Brazil
Prior art keywords
combinations
treatment
diseases involving
involving angiogenesis
formation
Prior art date
Application number
BR0008254-6A
Other languages
English (en)
Inventor
Peter David Davis
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of BR0008254A publication Critical patent/BR0008254A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

"COMBINAçõES PARA O TRATAMENTO DE DOENçAS QUE ENVOLVAM ANGIOGêNESE". Apresentam-se composições para a inibição da formação de nova vascularização por angiogênese, compreendendo a combinação de um agente de lesão da vascularização e um inibidor da formação ou da ação de óxido nítrico em sistemas de mamíferos. Também se apresentam o uso dessas combinações em medicamentos e kits desses compostos e o tratamento que emprega esses materiais.
BR0008254-6A 1999-02-16 2000-02-15 Combinações para o tratamento de doenças que envolvam angiogênese BR0008254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9903404.3A GB9903404D0 (en) 1999-02-16 1999-02-16 Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
PCT/GB2000/000511 WO2000048591A1 (en) 1999-02-16 2000-02-15 Combinations for the treatment of diseases involving angiogenesis

Publications (1)

Publication Number Publication Date
BR0008254A true BR0008254A (pt) 2001-11-06

Family

ID=10847791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008254-6A BR0008254A (pt) 1999-02-16 2000-02-15 Combinações para o tratamento de doenças que envolvam angiogênese

Country Status (21)

Country Link
US (2) US7087627B1 (pt)
EP (1) EP1161235B1 (pt)
JP (1) JP4708569B2 (pt)
KR (2) KR20070034642A (pt)
CN (1) CN1344159B (pt)
AT (1) ATE288264T1 (pt)
AU (1) AU775242B2 (pt)
BR (1) BR0008254A (pt)
CA (1) CA2362281C (pt)
DE (1) DE60017878T2 (pt)
DK (1) DK1161235T3 (pt)
ES (1) ES2237407T3 (pt)
GB (1) GB9903404D0 (pt)
HK (1) HK1040919B (pt)
IL (2) IL144847A0 (pt)
MX (1) MXPA01008245A (pt)
NO (1) NO20013966L (pt)
NZ (1) NZ513429A (pt)
PT (1) PT1161235E (pt)
WO (1) WO2000048591A1 (pt)
ZA (1) ZA200106688B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EE200200565A (et) 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
US20050153939A1 (en) 2003-09-10 2005-07-14 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
HRP20030382A2 (en) * 2000-10-27 2005-04-30 Aventis Pharma S.A. A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
AU2008202468B2 (en) * 2001-07-13 2011-08-11 Oxigene, Inc. Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
CN1527704B (zh) * 2001-07-13 2011-05-18 奥克斯吉尼有限公司 治疗眼病的组合物和微管蛋白结合剂用法
EP1287854B1 (en) * 2001-08-30 2005-11-30 Cancer Research Technology Limited Anti-cancer combinations of DMXAA and paclitaxel or docetaxel
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2007354255A1 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
PT2219451E (pt) 2007-11-21 2015-02-09 Oxigene Inc Processo para o tratamento de neoplasmas hematopoiéticos
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1095710A (zh) 1992-11-27 1994-11-30 惠尔康基金会集团公司 酶抑制剂
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5424447A (en) * 1993-07-07 1995-06-13 The Medical College Of Wisconsin Research Foundation, Inc. Heme binding compounds and use thereof
GB9320484D0 (en) * 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
WO1996018617A1 (en) 1994-12-12 1996-06-20 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1997032585A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

Also Published As

Publication number Publication date
DK1161235T3 (da) 2005-05-09
MXPA01008245A (es) 2002-10-23
KR20070034642A (ko) 2007-03-28
HK1040919A1 (en) 2002-06-28
AU2559000A (en) 2000-09-04
JP2002537251A (ja) 2002-11-05
IL144847A (en) 2006-10-31
GB9903404D0 (en) 1999-04-07
JP4708569B2 (ja) 2011-06-22
CA2362281C (en) 2008-11-18
IL144847A0 (en) 2002-06-30
ATE288264T1 (de) 2005-02-15
CA2362281A1 (en) 2000-08-24
KR20010102038A (ko) 2001-11-15
PT1161235E (pt) 2005-05-31
ZA200106688B (en) 2002-08-14
NO20013966D0 (no) 2001-08-15
EP1161235A1 (en) 2001-12-12
US7087627B1 (en) 2006-08-08
DE60017878D1 (de) 2005-03-10
EP1161235B1 (en) 2005-02-02
CN1344159B (zh) 2011-09-28
NZ513429A (en) 2003-10-31
HK1040919B (en) 2005-05-13
AU775242B2 (en) 2004-07-22
WO2000048591A1 (en) 2000-08-24
CN1344159A (zh) 2002-04-10
DE60017878T2 (de) 2006-01-26
US20060198846A1 (en) 2006-09-07
NO20013966L (no) 2001-10-15
ES2237407T3 (es) 2005-08-01

Similar Documents

Publication Publication Date Title
BR0008254A (pt) Combinações para o tratamento de doenças que envolvam angiogênese
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
HN2001000146A (es) Derivados de pirazol
BR9917089A (pt) Composições e métodos para distribuição mucosal
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
BR9916746A (pt) Compostos anti-inflamatórios que inibem adesão de célula
BR0307772A (pt) Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência
EP1113000A4 (en) BENZENE DERIVATIVES AND THEIR MEDICAL APPLICATION
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
DK0900233T3 (da) Steroid-nitrit- og -nitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
DK279790A (da) Aromatiske steroid-5-alfa-reduktaseinhibitorer
PT1169337E (pt) Nitratos esteroides para o tratamento de lesoes oxidativas e disfuncoes endoteliais
IT1285770B1 (it) Composti corticoidei
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
DK0912185T3 (da) Nye farmaceutiske sammensætninger indeholdende steroidnitratesterderivater, der kan anvendes som antiinflammatoriske lægemidler
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
DK0866870T3 (da) Vævsfaktor-Kunitz-domæne-fusionsproteiner som inhibitorer for faktor Vlla
TR200102448T2 (tr) COPD tedavisi için kontrollu salma formülasyonu.
UY27550A1 (es) Composición para catéter y usos de la misma
NO20031650D0 (no) Nye legemidler for leversykdommer

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.